{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T06:01:40Z","timestamp":1768456900237,"version":"3.49.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","journals.elsevierhealth.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.eururo.2014.08.011","type":"journal-article","created":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T04:24:43Z","timestamp":1409027083000},"page":"1109-1115","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":68,"title":["The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men"],"prefix":"10.1016","volume":"66","author":[{"given":"Moniek M.","family":"Vedder","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Esther W.","family":"de Bekker-Grob","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans G.","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Vickers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geert J.L.H.","family":"van Leenders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewout W.","family":"Steyerberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monique J.","family":"Roobol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2014.08.011_bib0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.eururo.2010.10.039","article-title":"EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease","volume":"59","author":"Heidenreich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0010","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/jnci\/95.12.868","article-title":"Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer","volume":"95","author":"Draisma","year":"2003","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.08.011_bib0015","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/sj.bjc.6605422","article-title":"Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer","volume":"101","author":"Heijnsdijk","year":"2009","journal-title":"Br J Cancer"},{"key":"10.1016\/j.eururo.2014.08.011_bib0020","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.juro.2006.08.068","article-title":"Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram","volume":"177","author":"Steyerberg","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0025","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/jnci\/djj131","article-title":"Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial","volume":"98","author":"Thompson","year":"2006","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2014.08.011_bib0030","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1097\/01.ju.0000158039.94467.5d","article-title":"Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen","volume":"173","author":"Karakiewicz","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0035","first-page":"5975","article-title":"DD3: a new prostate-specific gene, highly overexpressed in prostate cancer","volume":"59","author":"Bussemakers","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.eururo.2014.08.011_bib0040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrurol.2009.40","article-title":"The use of PCA3 in the diagnosis of prostate cancer","volume":"6","author":"Hessels","year":"2009","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0045","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1741-7015-6-19","article-title":"A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden","volume":"6","author":"Vickers","year":"2008","journal-title":"BMC Med"},{"key":"10.1016\/j.eururo.2014.08.011_bib0050","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/sj.bjc.6605815","article-title":"A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands","volume":"103","author":"Gupta","year":"2010","journal-title":"Br J Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2014.08.011_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1464-410X.2003.04389.x","article-title":"The story of the European Randomized Study of Screening for Prostate Cancer","volume":"92","author":"Schroder","year":"2003","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.08.011_bib0060","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2014.08.011_bib0065","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.eururo.2010.06.039","article-title":"Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test","volume":"58","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0070","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.eururo.2011.11.012","article-title":"Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators","volume":"61","author":"Roobol","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0075","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2009.24.1968","article-title":"Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication","volume":"28","author":"Vickers","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0080","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.eururo.2012.07.029","article-title":"A calculator for prostate cancer risk 4 years after an initially negative screen: findings from ERSPC Rotterdam","volume":"63","author":"Roobol","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0085","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/pros.20352","article-title":"ERSPC Rotterdam. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng\/ml (results of ERSPC, Rotterdam)","volume":"66","author":"Roobol","year":"2006","journal-title":"Prostate"},{"key":"10.1016\/j.eururo.2014.08.011_bib0090","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1177\/0272989X06295361","article-title":"Decision curve analysis: a novel method for evaluating prediction models","volume":"26","author":"Vickers","year":"2006","journal-title":"Med Decis Making"},{"key":"10.1016\/j.eururo.2014.08.011_bib0095","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/EDE.0b013e3181c30fb2","article-title":"Assessing the performance of prediction models: a framework for traditional and novel measures","volume":"21","author":"Steyerberg","year":"2010","journal-title":"Epidemiology"},{"key":"10.1016\/j.eururo.2014.08.011_bib0100","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1472-6947-8-53","article-title":"Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers","volume":"8","author":"Vickers","year":"2008","journal-title":"BMC Med Inform Decis Mak"},{"key":"10.1016\/j.eururo.2014.08.011_bib0105","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1002\/ijc.22427","article-title":"Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy","volume":"120","author":"Steuber","year":"2007","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2014.08.011_bib0110","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.eururo.2010.06.038","article-title":"External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome","volume":"58","author":"Auprich","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0115","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.eururo.2010.10.024","article-title":"Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging","volume":"59","author":"Auprich","year":"2011","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0120","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.eururo.2010.09.030","article-title":"Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (\u2265100)","volume":"58","author":"Roobol","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2013.04.040","article-title":"Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam","volume":"64","author":"Carlsson","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0130","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3111\/13696998.2012.757552","article-title":"Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France","volume":"16","author":"Malavaud","year":"2013","journal-title":"J Med Econ"},{"key":"10.1016\/j.eururo.2014.08.011_bib0135","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1464-410X.2011.10751.x","article-title":"Cost-effectiveness of Prostate Health Index for prostate cancer detection","volume":"110","author":"Nichol","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2014.08.011_bib0140","doi-asserted-by":"crossref","first-page":"288","DOI":"10.5301\/RU.2011.8875","article-title":"Analysis of costs of transrectal prostate biopsy","volume":"78","author":"Fandella","year":"2011","journal-title":"Urologia"},{"key":"10.1016\/j.eururo.2014.08.011_bib0145","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.eururo.2008.06.071","article-title":"Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy","volume":"54","author":"Haese","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0150","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.juro.2013.02.018","article-title":"PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study","volume":"190","author":"Gittelman","year":"2013","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0155","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/aje\/kwk052","article-title":"Relaxing the rule of ten events per variable in logistic and Cox regression","volume":"165","author":"Vittinghoff","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.eururo.2014.08.011_bib0160","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2009.10.031","article-title":"Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies","volume":"57","author":"Schr\u00f6der","year":"2010","journal-title":"Eur Urol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814007532?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283814007532?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,30]],"date-time":"2018-09-30T05:23:20Z","timestamp":1538285000000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283814007532"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0302283814007532"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2014.08.011","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Added Value of Percentage of Free to Total Prostate-specific Antigen, PCA3, and a Kallikrein Panel to the ERSPC Risk Calculator for Prostate Cancer in Prescreened Men","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2014.08.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}